Purpose: Azacitidine and decitabine are hypomethylating agents (HMA), that is, both inhibit
and deplete DNA methyltransferase 1 (DNMT1). HMAs are standard single-agent therapies …

Abstract Alveolar Soft Part Sarcoma is one of the less commonly diagnosed soft tissue
sarcoma subtypes, an infrequent subtype within the already rare category of human …

Small cell lung cancers (SCLCs) rapidly resist cytotoxic chemotherapy and immune
checkpoint inhibitor (ICI) treatments. New, non-cross-resistant therapies are thus needed …

Acute myeloid leukemia (AML), the most common acute leukemia in adults, increases
exponentially with age. While a number of recent advances have improved treatment, high …

Purpose: Induction chemotherapy results in complete remission (CR) rates of 20% to 50%
among patients with poor-risk AML. Selinexor is an oral selective inhibitor of nuclear export …

Chronic inflammation, while subtle, puts the body in a constant state of alert and is
associated with a number of diseases, including cancer and cardiovascular diseases. It …

Background Improving the poor prognosis of infant leukaemias remains an unmet clinical
need. This disease is a prototypical fusion oncoprotein‐driven paediatric cancer, with MLL …

Epigenetic variations can play remarkable roles in different normal and abnormal situations.
Such variations have been shown to have a direct role in the pathogenesis of various …

Acute Myelogenous Leukemia (AML) is a malignant disease of the hematopoietic cells,
characterized by impaired differentiation and uncontrolled clonal expansion of myeloid …

NPM1 is the most frequently mutated gene in adults with acute myeloid leukemia (AML). The
interaction between mutant NPM1 (NPM1c) and exportin-1 (XPO1) causes aberrant …